touchENDOCRINOLOGY were delighted to speak to Jose Florez, Committee Chair for the ADA’s Scientific Sessions Meeting Planning Committee, about his highlights of the conference, organising such a large virtual platform, advances in genetics in patients with type 2 diabetes and gestational diabetes and how healthcare biobanks can accelerate clinical research.
1. What were your highlights of the 80th ADA 2020 Virtual Scientific Sessions? (0:06)
2. What was your experience organising a virtual conference of this size, and are you pleased with how it has turned out? (1:41)
3. Please summarise the research that you are involved in on genetics in patients with type 2 diabetes and gestational diabetes (3:09)
4. Please provide an overview of the benefits of healthcare biobanks and how they can accelerate clinical research (5:24)
Speaker disclosure: Jose Florez has received one honorarium from Novo Nordisk to speak at a scientific meeting on a topic of his choice.
Support: Interview commissioned and filming supported by Touch Medical Media.
Filmed in coverage of the ADA 2020 Virtual 80th Scientific Sessions
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!